1. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5(7):788-792.
2. Stevens JHP, O’Hanley JM, Shapiro, et al. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest. 1986;77(6):1812-1816.
3. Fujita E, FarkasI, Campbell W, et al. Inactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5a. J Immunol. 2004;172(10):6382-6387.
4. Okada N, Asai S, Hotta A, et al. Increased inhibitory capacity of an anti-C5a complementary peptide following acetylation of N-terminal alanine. Microbiol Immunol. 2007;51(4):439-443.
5. Wang H, Bloom O, Zhang M, et al. HMGB-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-251.
6. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003;9(5):517-524.
7. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26(2):174-179.
8. Yang H, OchaniM, Li J, et al. Reversing established sepsis with antagonists of endogeneous high-mobility group box 1. Proc Natl Acad Sci U S A. 2004;101(1):296-301.
9. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors.Am J Physiol Cell Physiol. 2005;290:C917-C924.
10. Hussein MH, Kato S, Goto T, et al. An acetylated anti-C5a complementary peptide reduced cytokines and free radicals and prolongs survival time in a neonatal sepsis model. Mol Immunol. 2009;46(52):2825-2829.
11. Chen NJ, Mirtsos C, Suh D, et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature. 2007;446(7132):203-207.
12. Klune JR, Dhupar R, Cardinal, J, et al. HMGB1:endogeneous danger signaling. Mol Med. 2008;(7-8):476-484.
13. Rittirsch D, Flierl MA, Nadeau, et al. Functional roles for C5a receptors in sepsis. Nat Med. 2008;14(5):551-557.